Nls Pharmaceutics Ltd Quick Ratio (NLSP) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Nls Pharmaceutics Ltd  (NASDAQ: NLSP)

Nls Pharmaceutics Ltd's Quick Ratio

NLSP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Nls Pharmaceutics Ltd's Cash & cash equivalent grew by 100 % in the Q4 2025 sequentially, faster than Current Liabilities, this led to improvement in Nls Pharmaceutics Ltd's Quick Ratio to 0.86, Quick Ratio remained below Nls Pharmaceutics Ltd average.

Within Major Pharmaceutical Preparations industry 393 other companies have achieved higher Quick Ratio than Nls Pharmaceutics Ltd in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 0 to 2363.

Explain Quick Ratio?
How much Cash & cash equivalents NLSP´s has?
What are NLSP´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NLSP Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 114.75 % -26.07 % -84.84 % -47.03 % -51.28 %
Y / Y Cash & cash equivalent Change 238.62 % 298.19 % 24.79 % 145.19 % -21.28 %
Quick Ratio MRQ 0.86 0.52 2.07 0.52 0.54
NLSP's Total Ranking # 2363 # 0 # # #
Seq. Current Liabilities Change 22.5 % 183.28 % -64.7 % 75.3 % -57.83 %
Seq. Cash & cash equivalent Change 100 % -28.36 % 39.59 % 69.31 % 135.18 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 394
Healthcare Sector # 726
Overall Market # 2363


Quick Ratio Statistics
High Average Low
8.3 1.36 0.07
0   (Dec 31 2020)




Financial Statements
Nls Pharmaceutics Ltd's Current Liabilities $ 5 Millions Visit NLSP's Balance sheet
Nls Pharmaceutics Ltd's Cash & cash equivalent $ 4 Millions Visit NLSP's Balance sheet
Source of NLSP's Sales Visit NLSP's Sales by Geography


Cumulative Nls Pharmaceutics Ltd's Quick Ratio

NLSP's Quick Ratio for the trailling 12 Months

NLSP Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -41.71 % -56.62 % -54.96 % -15.72 % 16.47 %
Y / Y Cash & cash equivalent TTM Growth 127.85 % 57.7 % 20.6 % -47.43 % -74.51 %
Quick Ratio TTM 0.79 0.72 0.52 0.3 0.2
Total Ranking TTM # 4827 # 0 # # #
Seq. Current Liabilities TTM Growth 22.39 % -10.76 % -37.61 % -14.46 % -8.91 %
Seq. Cash & cash equivalent TTM Growth 35.35 % 23.13 % 9.37 % 25 % -6.32 %

Quick ratio ranking by company, industry and sector >> Back to NLSP Financial Strength Comparisons >> Go to Compare NLSP Quick Ratio to its Competitors

On the trailing twelve months basis NLSP Cash & cash equivalent more than doubled by 238.62 % in Q4 2025 year on year, faster than Current Liabilities, this led to increase in in Nls Pharmaceutics Ltd's Quick Ratio to 0.79, Quick Ratio remained below NLSP average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 499 other companies have achieved higher Quick Ratio than Nls Pharmaceutics Ltd. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 0 to 4827.

Explain Quick Ratio?
How much Cash & cash equivalents NLSP´s has?
What are NLSP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 500
Healthcare Sector # 1016
Within the Market # 4827


trailing twelve months Quick Ratio Statistics
High Average Low
2.66 1.29 0.15
(Dec 31 2022)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Satellos Bioscience Inc   2.35 $ 9.804  Millions$ 4.177  Millions
Insmed Inc  2.31 $ 1,430.047  Millions$ 618.925  Millions
Actuate Therapeutics Inc   2.31 $ 13.159  Millions$ 5.707  Millions
Elicio Therapeutics Inc   2.29 $ 18.563  Millions$ 8.110  Millions
Lantern Pharma Inc   2.29 $ 10.119  Millions$ 4.423  Millions
Palatin Technologies Inc   2.29 $ 14.476  Millions$ 6.333  Millions
Regeneron Pharmaceuticals Inc   2.26 $ 8,605.200  Millions$ 3,815.400  Millions
Ultragenyx Pharmaceutical Inc   2.24 $ 680.000  Millions$ 303.000  Millions
Corcept Therapeutics Inc  2.24 $ 372.152  Millions$ 166.085  Millions
Petros Pharmaceuticals inc   2.24 $ 5.137  Millions$ 2.293  Millions
Galectin Therapeutics Inc   2.22 $ 17.726  Millions$ 7.967  Millions
Prf Technologies Ltd   2.22 $ 5.207  Millions$ 2.348  Millions
Filana Therapeutics Inc   2.20 $ 95.502  Millions$ 43.470  Millions
Mustang Bio inc   2.18 $ 17.266  Millions$ 7.914  Millions
Dogwood Therapeutics inc   2.17 $ 6.525  Millions$ 3.002  Millions
Omeros Corporation  2.17 $ 171.804  Millions$ 79.208  Millions
Gossamer Bio Inc   2.16 $ 136.932  Millions$ 63.435  Millions
Larimar Therapeutics Inc   2.11 $ 136.852  Millions$ 64.795  Millions
Cue Biopharma Inc   2.09 $ 28.229  Millions$ 13.494  Millions
Schrodinger Inc   2.09 $ 395.464  Millions$ 189.136  Millions
Allarity Therapeutics Inc   2.09 $ 14.687  Millions$ 7.030  Millions
Imunon Inc   2.08 $ 8.781  Millions$ 4.217  Millions
Prelude Therapeutics Inc  2.05 $ 103.214  Millions$ 50.250  Millions
Biomarin Pharmaceutical Inc  2.05 $ 1,560.609  Millions$ 762.698  Millions
Bridgebio Pharma Inc   2.04 $ 587.482  Millions$ 287.971  Millions
Scisparc Ltd  2.04 $ 4.591  Millions$ 2.253  Millions
Veru Inc   2.03 $ 15.795  Millions$ 7.785  Millions
Travere Therapeutics Inc   2.02 $ 322.796  Millions$ 159.904  Millions
Xoma Royalty Corporation  2.02 $ 82.908  Millions$ 41.114  Millions
Ptc Therapeutics inc   2.00 $ 1,945.371  Millions$ 973.104  Millions

Date modified: 2026-07-07T12:13:02+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.